MedTrace Logo

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02112838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2019-06-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

Conditions

Interventions

DRUG

Fostamatinib 150 mg

Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks

DRUG

Fostamatinib 100 mg

Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks

DRUG

Placebo

Placebo tablet twice daily by mouth, over the course of 24 weeks

Sponsors & Collaborators

  • Rigel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Rigel Pharmaceuticals, Inc. · Rigel Pharmaceuticals,Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-03-23
Completion
2018-11-12

Countries

  • United States
  • Austria
  • Germany
  • Hong Kong
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02112838 on ClinicalTrials.gov